Targets › FASLG
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Feb 2028.
Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells. Involved in cytotoxic T-cell-mediated apoptosis, natural killer cell-mediated apoptosis and in T-cell development. (UniProt, P48023)
Open in Phaseline: the race on FASLG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Providence Health & Services | M3T01 Fully human IgG4/kappa monoclonal antibody targeting FasL (Fas ligand) | FASLG | Phase 1 | Advanced Solid Tumors | Feb 2028 |
Advanced Solid Tumors (1)
mixed (1)
Providence Health & Services (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.